# Elutia, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Elutia, Inc). ## Overview Elutia Inc. develops proprietary biologic matrix products designed to improve how implanted devices and surgical materials interact with the body. The company has shifted toward a smaller core business after selling its CIED and orthobiologics businesses, and now focuses on biologic products for surgical reconstruction and cardiovascular repair, including SimpliDerm and its NXT-41 pipeline. ## Products & services • SimpliDerm human acellular dermal matrix for soft tissue reconstruction • Cardiovascular repair products: ProxiCor, VasCure, and Tyke • NXT-41 and NXT-41x drug-eluting biomatrix development • Prior CIED envelope products: EluPro, CanGaroo, CanGaroo RM - **Soft tissue reconstruction** (55%) — Human acellular dermal matrix products used in reconstructive surgery and wound-related applications. - **Cardiovascular repair** (25%) — Biologic repair products used in vascular and cardiovascular surgical procedures. - **Pipeline and development programs** (0%) — NXT-41 and NXT-41x programs intended to extend the biomatrix platform into new indications. - **Discontinued CIED products** (20%) — Cardiac implantable electronic device envelope products sold in the 2025 divestiture. - SimpliDerm hADM for soft tissue reconstruction - ProxiCor, VasCure, and Tyke cardiovascular repair matrices - NXT-41 and NXT-41x next-generation biomatrix pipeline - Drug-eluting biomatrix products for surgical reconstruction - Former CIED envelope products sold in 2025 divestiture ## Customers Elutia sells primarily to hospitals and other healthcare facilities, with products used by surgeons in reconstructive and cardiovascular procedures. Prior to the 2025 divestiture, its CIED products were used by electrophysiologists and neurosurgeons; the remaining business is centered on surgical end users and the facilities that purchase implantable biologic materials. - **Hospitals and healthcare facilities** (primary) — Buy biologic matrices and repair products for use in operative procedures and implanted reconstruction. - **Plastic and reconstructive surgeons** (primary) — Use SimpliDerm in soft tissue reconstruction where biologic integration and clinical outcomes matter. - **Cardiovascular surgeons** (secondary) — Buy cardiovascular repair products for vascular reconstruction and patching applications. - **Electrophysiologists and neurosurgeons** (secondary) — Previously bought CIED envelope products such as EluPro and CanGaroo before the 2025 sale. - Hospitals and healthcare facilities buying implantable biologic matrices - Plastic and reconstructive surgeons using SimpliDerm - Cardiovascular surgeons using ProxiCor, VasCure, and Tyke - Electrophysiologists and neurosurgeons were key CIED users before divestiture - Purchasers value efficacy, ease of use, reimbursement, and support ## Geography Elutia is a U.S.-based company with headquarters and primary operations in Gaithersburg, Maryland, plus a corporate office in San Diego. Its commercial activity has been concentrated in the United States, where it sold products through direct sales, independent agents, and, previously, a distribution partner for CIED products. - Headquartered in Gaithersburg, Maryland - Corporate office in San Diego, California - Primary commercial market is the United States - Products shipped directly to hospitals and healthcare facilities - Former Roswell and Richmond facilities were divested ## Strategy Elutia is repositioning around its remaining biologic matrix platform after divesting non-core businesses. Near term, the company is focused on commercializing SimpliDerm and cardiovascular products while funding NXT-41 and NXT-41x development, with liquidity and capital access central to execution. - **Commercialize core biologic products** (short-term) — The remaining business depends on growing SimpliDerm and cardiovascular sales to replace divested revenue streams. - **Advance NXT-41 and NXT-41x** (medium-term) — The pipeline is intended to extend the biomatrix platform into new applications and support future growth. - **Strengthen liquidity and capital flexibility** (short-term) — The company expects operating losses and needs funding to support development and commercialization. - Focus on core biologic matrix products after divestitures - Commercialize SimpliDerm and cardiovascular repair portfolio - Advance NXT-41 and NXT-41x toward FDA authorization - Use direct sales and independent agents to expand market access - Preserve liquidity through product sales, equity, and asset actions ## Risks Elutia remains exposed to commercialization risk because its future depends on a small set of biologic products and on successful development of NXT-41 and NXT-41x. The company also faces going-concern and financing risk, plus intense competition from established biologic, bovine, and synthetic alternatives in surgical repair markets. - **Commercialization dependence on a narrow product base** [high] — After divestitures, the company relies on a smaller portfolio to generate revenue and fund operations. - **Going-concern and financing risk** [critical] — Management disclosed substantial doubt about the ability to continue as a going concern without additional funding. - **Competitive pressure in biologic reconstruction markets** [high] — Competitors offer established acellular dermis, bovine, and synthetic alternatives with pricing and reimbursement advantages. - **Regulatory and development risk** [high] — NXT-41 and NXT-41x require successful development and FDA marketing authorization before they can contribute meaningfully. - Dependence on SimpliDerm and cardiovascular product adoption - Pipeline risk for NXT-41 and NXT-41x development and FDA clearance - Going-concern and capital-raising risk due to expected losses - Intense competition from larger biologic and synthetic product makers - Reimbursement and payor coverage can affect procedure adoption ## Accounting Revenue is recognized at the point control transfers, but consigned inventory and distributor-held inventory can delay recognition until use or implantation, which affects quarterly timing. Investors should also watch discontinued-operations accounting for the 2023 orthobiologics sale and 2025 CIED sale, plus estimates tied to the Ligand revenue interest obligation, contingent liabilities, and going-concern disclosures. - **Revenue recognition timing** — Quarterly sales can be lumpy and harder to compare - **Discontinued operations accounting** — Reported revenue and margins no longer reflect the divested businesses - **Revenue interest obligation** — Affects expense recognition and cash flow - **Going-concern assessment** — Signals financing dependence and potential dilution - Point-in-time revenue recognition for shipped product sales - Delayed revenue on consigned or implanted inventory - Discontinued operations from orthobiologics and CIED divestitures - Revenue interest obligation and minimum payment estimates - Going-concern disclosure affects valuation and comparability --- *Last updated: 2026-09-24T11:49:20.714382+00:00*